A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Multicenter Study to Evaluate the Efficacy of FX-322 Administered by Intratympanic Injection in Adults with Acquired Sensorineural Hearing Loss

Last updated: March 7, 2022
Sponsor: Frequency Therapeutics
Overall Status: Active - Recruiting

Phase

2

Condition

Hearing Loss

Hearing Impairment

Treatment

N/A

Clinical Study ID

TX291466
  • Ages 18-65
  • All Genders

Study Summary

To evaluate the safety of the Investigational Product and explore its effectiveness in restoring hearing function by regenerating cells in the ear that are necessary for healthy hearing.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Documented medical history of acquired hearing loss

Exclusion

Exclusion Criteria:

  • Evidence of middle ear disease

Study Design

Study Start date:
Estimated Completion Date:

Study Description

This trial will compare an Investigational Product injection to an injection of a placebo

[https://www.centerwatch.com/clinical-trials/listings/285718/fx-322-in-adults- with-acquired-sensorineural-hearing- loss/?q=FX+322&place=&geo_lat=&geo_lng=&user_country=&query=FX%20322&rnk=1](https://www.centerwatch.com/clinical- trials/listings/285718/fx-322-in-adults-with-acquired-sensorineural-hearing- loss/?q=FX+322&place=&geo_lat=&geo_lng=&user_country=&query=FX%20322&rnk=1)

Connect with a study center

  • Piedmont Ear, Nose, and Throat Associates

    Winston-Salem, North Carolina 27103
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.